- Home
- RMCF vs INDP Comparison
RMCF vs INDP Comparison
Compare RMCF & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RMCF | INDP |
|---|---|---|
| Founded | 1981 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4M | 4.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RMCF | INDP |
|---|---|---|
| Price | $1.57 | $2.05 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 28.6K | ★ 35.5K |
| Earning Date | 01-13-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $29,988,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 8.09 | N/A |
| 52 Week Low | $1.12 | $1.65 |
| 52 Week High | $3.18 | $47.60 |
Technical Indicators
Market Signals| Indicator | RMCF | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 46.91 | 39.10 |
| Support Level | $1.50 | $2.39 |
| Resistance Level | $1.64 | $2.94 |
| Average True Range (ATR) | 0.07 | 0.20 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 30.43 | 8.29 |
Price Performance
Historical ComparisonAbout RMCF Rocky Mountain Chocolate Factory Inc.
Rocky Mountain Chocolate Factory Inc operates as a manufacturer of chocolate candies and confectionery products. The business activity of the firm functions through Franchising, Manufacturing, Retail Stores, U-Swirl Operations, and Other t. The products of the company include varieties of Clusters, Caramels, Creams, Toffees, Mints, and Truffles.
About INDP Indaptus Therapeutics Inc.
Indaptus Therapeutics Inc is a pre-clinical biotechnology company engaged in developing a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. It has developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. The company's clinical candidate Decoy20, has the ability to elicit single-agent activity and durable anti-tumor responses in the combination setting against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma models.